News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eisai Company, Ltd. (ESALY.PK) , Abbott Japan To Collaborate To Develop D2E7 Anti-rheumatic Agent Seeking Psoriasis Indication



10/19/2005 5:13:16 PM

Tokyo (JCNN) - On April 11, Eisai (TSE: 4523) and Abbott Japan jointly announced that they have concluded a joint development agreement for D2E7, an anti-rheumatic agent owed by Abbott GmbH, the parent company of Abbott Japan. Under the terms of the agreement, the two companies will clinically develop D2E7 seeking an indication for psoriasis.

Read at JCN Newswire


comments powered by Disqus
   
Psoriasis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES